Invuity Names Greg Lucier Chairman
November 30 2015 - 6:30AM
Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology
company, announced today that life sciences industry luminary
Gregory T. Lucier has been appointed to the role of Chairman of its
Board of Directors, effective December 31, 2015. Lucier, who
is the chief executive officer of Nuvasive, Inc. (Nasdaq:NUVA), has
served on the Invuity board since October 2014. He will take the
place of Gregory B. Brown, M.D., who will resign from the Board
effective December 31, 2015. Brown has served as a member of
the board of directors since February 2014 and as Chairman since
March 2015.
"Invuity is expanding its operations and commercial footprint at
a fast pace across multiple surgical specialties, and this is an
optimal time for Greg Lucier, a proven industry veteran, to
transition to a new role on the Board," said Invuity Chief
Executive Officer Philip Sawyer. "Greg has already proven to
be a valuable resource, and his understanding of how truly unique,
high-growth organizations are built is a tremendous asset."
Lucier was named chief executive officer at Nuvasive in May
2015. Prior to Nuvasive, Lucier was the chairman and chief
executive officer of Life Technologies Corporation, a global
life sciences company that was acquired by Thermo Fisher Scientific
in 2013. At Life Technologies, Lucier led the transformation of the
company from a biotechnology tools company with sales of $600
million into one of the largest life sciences companies in the
world with sales of close to $4 billion, ultimately being sold
to Thermo Fisher for more than $16 billion. Lucier
led Life Technologies' expansion into broad new categories as well
as its growth into a leading global entity.
"Invuity is an innovative and rapidly expanding enterprise that
has the potential to truly transform surgery," said
Lucier. "On behalf of the board and the entire company, I
would like to thank Greg Brown for his service and leadership to
Invuity. I am very much looking forward to supporting and advising
the team and continuing the track record of superior governance as
Invuity continues to build a world-class organization."
Prior to Life Technologies, Lucier held several senior
management positions with General Electric Company (GE) from 1995
to 2003, and was most recently chief executive officer and
president of Medical Systems Information Technologies for GE
Healthcare.
Lucier received a Bachelor of Science degree with high
distinction in Industrial Engineering from Pennsylvania State
University and a Master of Business Administration degree from
The Harvard Business School.
About Invuity®
Invuity, Inc. is a medical technology company focused on
developing and marketing advanced photonics devices to improve the
ability of surgeons to illuminate and visualize the surgical cavity
during open minimally invasive and minimal access surgery. The
company's patented Intelligent Photonics™ technology enables
enhanced surgical precision, efficiency and safety by providing
superior visualization. Clinical applications include breast and
thyroid oncology, plastic reconstructive, spine, orthopedic,
cardiothoracic and general surgery among
others. Invuity is headquartered in San Francisco,
CA. For more information, visit www.invuity.com.
Forward-Looking Statements
This announcement contains forward-looking statements that
involve risks and uncertainties, including statements regarding
market opportunities and potential results from future new
initiatives. Actual results could differ materially from those
projected in the forward-looking statements as a result of certain
risk factors, including, but not limited to: fluctuations in demand
or failure to gain market acceptance for the Company's devices; the
Company's ability to demonstrate to and gain approval from
hospitals to use the Company's devices; the highly competitive
business environment for surgical medical devices; the Company's
ability to sell its devices at prices that support its current
business strategies; difficulty forecasting future financial
performance; protection of the Company's intellectual property; and
compliance with necessary regulatory clearances or approvals. The
Company undertakes no obligation to update the forward-looking
information in this release. More information about potential
factors that could affect the Company's business and financial
results is included in its filings with the Securities and Exchange
Commission, including, without limitation, under the captions:
"Management's Discussion and Analysis of Financial Condition and
Results of Operations," and "Risk Factors," which are on file with
the Securities and Exchange Commission.
CONTACT: Media:
Miranda Duncan
Waggener Edstrom
415-342-9430
media@invuity.com
Investors:
Matt Clawson
Pure Communications
949-370-8500
irdept@invuity.com
Nuvasive (NASDAQ:NUVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nuvasive (NASDAQ:NUVA)
Historical Stock Chart
From Apr 2023 to Apr 2024